This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Eisai.
Reference
Tremblay G, et al. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea. ClinicoEconomics and Outcomes Research : 19 Sep 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S110553
Rights and permissions
About this article
Cite this article
Eribulin cost effective for MBC in South Korea. PharmacoEcon Outcomes News 763, 15 (2016). https://doi.org/10.1007/s40274-016-3428-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3428-z